Biosimilars/General
Also noted on biosimilars: 6 April 2012
Amgen and AstraZeneca make monoclonal antibody deal
Biotech giant Amgen and pharma major AstraZeneca announced on 2 April 2012 an agreement to jointly develop and commercialise five monoclonal antibodies from Amgen’s clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab [AMG 827]), which are expected to be used to treat inflammatory diseases.
As part of the deal AstraZeneca will make an upfront payment of US$50 million and the companies will then share both costs and profits. The collaboration will provide Amgen with additional resources to optimally progress its portfolio and Amgen will benefit from the strong respiratory, inflammation and asthma development expertise of MedImmune–AstraZeneca’s biologicals arm.
Related articles
Amgen finally jumps on biosimilars bandwagon
AstraZeneca expands its generics business with Indian agreements
Source: Amgen, AstraZeneca
BIO and GPhA support biosimilar and generic user fees
Both the Biotechnology Industry Organization (BIO) and the Generic Pharmaceutical Association (GPhA) have expressed their support of user fees for biosimilars and generics.
Biosimilars will not be able to use ANDA pathway to approval
FDA’s highly anticipated guidance for biosimilars finally arrived on 10 February 2012 with the release of three draft guidance documents [1]. Some have complained that the guidance is too vague, however, FDA’s denial of three citizen’s petitions have perhaps made some issues clearer.
FDA announces public hearing on biosimilars’ guidelines
FDA has announced a one-day public hearing to be held on 11 May 2012, in Silver Spring, Maryland, USA. During the meeting FDA hopes ‘to obtain input on recently issued draft guidelines relating to the development of biosimilar products.’
Also noted on biosimilars: 16 March 2012
Boehringer Ingelheim expands biologicals manufacturing capacity
Boehringer Ingelheim announced on 29 February 2012 the expansion of its biopharmaceutical development and manufacturing capabilities at its cell culture and microbial sites in Biberach, Germany and Vienna, Austria. The company has invested around Euros 17 million in order to improve good manufacturing practice and to expand cell banking, process science, cell line development and quality laboratories.
Source: Boehringer Ingelheim
WHO definitions of biosimilars
Confusion often surrounds terms used in the global field of generics and biosimilars [1].
Biosimilars interchangeability, increased costs and burden for FDA
Biosimilars manufacturers in the US are faced with many hurdles, including untested regulatory pathways, patent challenges and manufacturing issues associated with making such complicated molecules. On top of this drugmakers also need to take into account the higher marketing costs that may be associated with biosimilars.
Quality by design in biomanufacturing
In January 2011, FDA published its long-awaited guidance for industry on Process Validation: General Principles and Practices [1].This replaces the previous 1987 version (updated 2004) and it is understandably a big change for some whose whole career has been dominated by the previous approach. The question is: why was a change needed and how drastic is it?
Top developments in biosimilars during 2011
Over the past year, a lot has happened in the biosimilars industry.
FDA biosimilar user fees meeting
FDA announced a public meeting to be held on 16 December 2011 to discuss its recommendations for the agency’s biosimilars user fee programme for 2013–17.
